{"id":97056,"date":"2025-08-05T07:05:48","date_gmt":"2025-08-05T05:05:48","guid":{"rendered":"https:\/\/www.formycon.com\/?page_id=97056"},"modified":"2026-04-29T08:54:22","modified_gmt":"2026-04-29T06:54:22","slug":"supervisory-board-of-formycon-ag","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/","title":{"rendered":"Supervisory Board"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221;]Supervisory Board[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243;]Strategic advice with a broad perspective[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243; uncode_shortcode_id=&#8221;885164&#8243;]The Supervisory Board of Formycon has many years of entrepreneurial experience.[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; uncode_shortcode_id=&#8221;200169&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;144280&#8243;][vc_single_image media=&#8221;97221&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;113136&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;177555&#8243;]<strong><em>From left to right: <\/em>Wolfgang Essler <\/strong>(Chairman of the Supervisory Board)<strong>, Colin Bond<\/strong> (Deputy Chairman of the Supervisory Board), <strong>Nicholas Haggar<\/strong> (Member of the Supervisory Board), <strong>Klaus R\u00f6hrig<\/strong> (Member of the Supervisory Board), <strong>Dr. Bodo Coldewey<\/strong> (Member of the Supervisory Board), <strong>Dr. Graham Dixon<\/strong> (Member of the Supervisory Board).[\/vc_column_text][vc_empty_space empty_h=&#8221;1&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;2&#8243; bottom_padding=&#8221;5&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_tabs history=&#8221;yes&#8221;][vc_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; tab_id=&#8221;1658847619109-3-8&#8243; title=&#8221;Wolfgang Essler&#8221; slug=&#8221;wolfgang-essler&#8221;][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading text_size=&#8221;h1&#8243; text_weight=&#8221;300&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;167938&#8243;]Wolfgang Essler[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;168015&#8243;]Chairman of the Supervisory Board<br \/>\nDeputy Chairman of the Nomination and Remuneration Committee[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;156628&#8243;]Member since July 25, 2023<br \/>\nElected until the end of the Annual General Meeting 2027[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;455636&#8243;]<strong>Wolfgang Essler,\u00a0<\/strong>who was born on October 20, 1972 in Munich, Germany, studied business administration at the University of Augsburg from 1992 until 1998. He began his professional career in the consulting firms O&amp;R Corporate Finance GmbH (1998-2008) and Duff &amp; Phelps GmbH (2008-2010) with a focus on corporate finance and transactions, followed as a board member at the investment company balandis real estate ag and predecessor companies (2010-2023). Since 2021, he is chief representative (<em>Generalbevollm\u00e4chtigter<\/em>) of ATHOS and managing director of Santo Holding (Deutschland) GmbH, i.e. of one of our Major Shareholder.[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; uncode_shortcode_id=&#8221;676607&#8243; sep_color_type=&#8221;uncode-palette&#8221; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;356575&#8243;]Alongside his office as a member of the Supervisory Board, Wolfgang Essler is, a member of the administrative or supervisory bodies of and\/or a partner in the following companies and partnerships outside Formycon:<\/p>\n<p><strong>Currently<\/strong>:<\/p>\n<ul>\n<li>Vanguard AG, Berlin, Germany, Deputy Chairman of the Supervisory Board;<\/li>\n<li>Mega Pharma Holding Uruguay S.A., Montevideo, Uruguay, member of the non-executive Board of Directors;<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; tab_id=&#8221;1719590951402-4-9&#8243; title=&#8221;Colin Bond&#8221; slug=&#8221;colin-bond&#8221;][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading text_size=&#8221;h1&#8243; text_weight=&#8221;300&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;205282&#8243;]Colin Bond[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;489234&#8243;]Deputy Chairman of the Supervisory Board<br \/>\nChairman of the Audit Committee<br \/>\nMember of the Nomination and Remuneration Committee[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;102335&#8243;]<\/p>\n<div class=\"vc_row row-internal row-container\">\n<div class=\"row row-child\">\n<div class=\"wpb_row row-inner\">\n<div class=\"wpb_column pos-top pos-center align_center column_child col-lg-12 single-internal-gutter\">\n<div class=\"uncol style-light\">\n<div class=\"uncoltable\">\n<div class=\"uncell no-block-padding\">\n<div class=\"uncont\">\n<div class=\"uncode_text_column\">\n<p>Member since October 1, 2024<br \/>\nElected until the end of the Annual General Meeting 2028<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;160269&#8243;]<strong>Colin Michael Bond\u00a0<\/strong>who was born on January 26, 1960 in Upminster, United Kingdom, holds a Bachelor of Science degree in pharmacy and a master\u2019s degree in business administration from London Business School. During his early career, Colin Michael Bond worked as auditor and management consultant for PricewaterhouseCoopers, Arthur Andersen and Procter &amp; Gamble. From 2010 to 2016, he served as Chief Financial Officer (CFO) of Evotec SE, which is listed on the Frankfurt Stock Exchange (Prime Standard) as well as NASDAQ. From 2016 to 2022, Colin Michael Bond served as Chief Financial Officer (CFO) of Vifor Pharma Management AG. From 2022 to June\u00a02024, he served as Chief Financial Officer (CFO) of Sandoz AG. Colin Michael Bond is a Fellow of the Institute of Chartered Accountants in England and Wales, and a member of the Royal Pharmaceutical Society of Great Britain.[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; uncode_shortcode_id=&#8221;157313&#8243; sep_color_type=&#8221;uncode-palette&#8221; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;956565&#8243;]Alongside his office as a member of the Supervisory Board, Colin Bond is, a member of the administrative or supervisory bodies of and\/or a partner in the following companies and partnerships outside Formycon:<\/p>\n<p><strong>Currently<\/strong>:<\/p>\n<ul>\n<li>BioPharma Credit Plc, Leeds, United Kingdom, member of the Board of Directors;<\/li>\n<li>Agomab Therapeutics NV, Antwerp, Belgium, member of the Board of Directors;<\/li>\n<li>Oxford Biomedica PLC, Oxford, United Kingdom, member of the Board of Directors;<\/li>\n<li>OneSource Specialty Pharma Ltd, Bangalore, India, member of the Board of Directors;<\/li>\n<li>Medichem, S.A., Barcelona, Spain, member of the Board of Directors;<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Nicholas Haggar&#8221; tab_id=&#8221;1534350364019-2-81534351033225&#8243; slug=&#8221;nicholas-haggar&#8221;][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading text_size=&#8221;h1&#8243; text_weight=&#8221;300&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;130562&#8243;]Nicholas Haggar[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;785204&#8243;]Member of the Supervisory Board<br \/>\nMember of the Audit Committee<br \/>\nChairman of the Nomination and Remuneration Committee[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;951883&#8243;]<\/p>\n<div class=\"vc_row row-internal row-container\">\n<div class=\"row row-child\">\n<div class=\"wpb_row row-inner\">\n<div class=\"wpb_column pos-top pos-center align_center column_child col-lg-12 single-internal-gutter\">\n<div class=\"uncol style-light\">\n<div class=\"uncoltable\">\n<div class=\"uncell no-block-padding\">\n<div class=\"uncont\">\n<div class=\"uncode_text_column\">\n<p>Member since June 12, 2024<br \/>\nElected until the end of the Annual General Meeting 2028<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;110640&#8243;]<strong>Nicholas Haggar\u00a0<\/strong>who was born on April 25, 1965 in Norwich, United Kingdom, has over thirty years of experience in building pharmaceutical businesses. With an Master of Business Administration from Cranfield School of Management and a Bachelors Degree in Industrial and Manufacturing Systems Engineering, Nicholas Haggar began his professional career in pharmaceutical technical operations before moving into commercial and enterprise leadership. Nicholas serves on the Zentiva board since 2023, having been Chief Executive Officer of Zentiva following its carve-out from Sanofi in 2018. Nicholas Haggar has been active in the biosimilar space for the last 15 years. Currently, he serves as Chief Executive of HealthQube Ltd., a UK-based investment, analytics and consultancy platform.[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; uncode_shortcode_id=&#8221;326103&#8243; sep_color_type=&#8221;uncode-palette&#8221; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;557202&#8243;]Alongside his office as a member of the Supervisory Board, Nicholas Haggar is, a member of the administrative or supervisory bodies of and\/or a partner in the following companies and partnerships outside Formycon:<\/p>\n<p><strong>Currently<\/strong>:<\/p>\n<ul>\n<li>Biocon Limited, Bangalore, India, independent member of the Board of Directors;<\/li>\n<li>Polpharma Group B.V., non-executive Chairman.Biocon Limited, Bangalore, India, independent member of the Board of Directors;<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;Klaus R\u00f6hrig&#8221; tab_id=&#8221;1534350362812-1-01534351033225&#8243; slug=&#8221;klaus-r\u00f6hrig&#8221;][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading text_size=&#8221;h1&#8243; text_weight=&#8221;300&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221;]Klaus R\u00f6hrig[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;182597&#8243;]Member of the Supervisory Board[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;129302&#8243;]Member since December 10, 2020<br \/>\nElected until the end of the Annual General Meeting 2029[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;307504&#8243;]<\/p>\n<div class=\"uncode_text_column text-lead\">\n<p><strong>Klaus R\u00f6hrig<\/strong>, who was born on July 21, 1977 in Vienna, Austria, studied business administration at the Vienna University of Economics and Business. He holds a Master of Economics and Business Administration from Vienna University of Economics and Business Administration. In 2000, he started his career at Credit Suisse First Boston in London, United Kingdom, focusing on corporate finance and M&amp;A for technology companies. From\u00a02002 to 2006, he worked for Mercury Capital GmbH in Vienna, Austria. In 2006, he joined Elliott Associates in London, United Kingdom, where he worked until 2012 and was responsible for the funds\u2019 investments in the German speaking countries. Since 2015, he is founding partner and Co-Chief Investment Officer of Active Ownership Capital S.\u00e0 r.l., an independent, partner-managed investment firm operating primarily in Continental Europe and Scandinavia.<\/p>\n<\/div>\n<div class=\"divider-wrapper \"><\/div>\n<p>[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; uncode_shortcode_id=&#8221;869506&#8243; sep_color_type=&#8221;uncode-palette&#8221; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;504373&#8243;]Alongside his office as a member of the Supervisory Board, Klaus R\u00f6hrig is, a member of the administrative or supervisory bodies of and\/or a partner in the following companies and partnerships outside Formycon:<\/p>\n<p><strong>Currently<\/strong>:<\/p>\n<ul>\n<li>Gerresheimer AG, D\u00fcsseldorf, Germany, member of the Supervisory Board;<\/li>\n<li>H2APEX Group SCA, Grevenmacher, Luxembourg, member of the Supervisory Board;<\/li>\n<li>MAM Baby AG, Wollerau, Switzerland, member of the Board of Directors.<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Dr. Bodo Coldewey&#8221; tab_id=&#8221;1534348708-1-991534351033225&#8243; slug=&#8221;dr-bodo-coldewey&#8221;][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading text_size=&#8221;h1&#8243; text_weight=&#8221;300&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;195502&#8243;]Dr. Bodo Coldewey[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;341494&#8243;]Member of the Supervisory Board<br \/>\nDeputy Chairman of\u00a0the Audit Committee[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;325026&#8243;]<\/p>\n<div class=\"vc_row row-internal row-container\">\n<div class=\"row row-child\">\n<div class=\"wpb_row row-inner\">\n<div class=\"wpb_column pos-top pos-center align_center column_child col-lg-12 single-internal-gutter\">\n<div class=\"uncol style-light\">\n<div class=\"uncoltable\">\n<div class=\"uncell no-block-padding\">\n<div class=\"uncont\">\n<div class=\"uncode_text_column\">\n<p>Member since June 12, 2024<br \/>\nElected until the end of the Annual General Meeting 2027<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;118587&#8243;]<strong>Dr. Bodo Coldewey<\/strong>, who was born on December 16, 1971 in Oldenburg, Germany, completed his studies in business engineering at the Technical University of Kaiserslautern and his doctorate at the Leipzig Graduate School of Management. In 1997, he began his professional career as consultant at KPMG Deutschland, where he worked until June 2000. In July 2000, he joined 3i Group plc as investment manager, where he worked until September 2002. From October 2002 to December 2011, Dr. Bodo Coldewey served as director of Oldenburgische Landesbank AG. Since 2012, he is managing director of the family office WEGA Invest GmbH.[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; uncode_shortcode_id=&#8221;202939&#8243; sep_color_type=&#8221;uncode-palette&#8221; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;200198&#8243;]Alongside his office as a member of the Supervisory Board, Dr. Bodo Coldewey is, a member of the administrative or supervisory bodies of and\/or a partner in the following companies and partnerships outside Formycon:<\/p>\n<p><strong>Currently<\/strong>: None<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Dr. Graham Dixon&#8221; tab_id=&#8221;1534348708-1-9915343510332257&#8243;][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading text_size=&#8221;h1&#8243; text_weight=&#8221;300&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;160444&#8243;]Dr. Graham Keith Dixon[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;930784&#8243;]Member of the Supervisory Board[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;172914&#8243;]Member since July 30, 2025<br \/>\nElected until the end of Annual General Meeting 2029[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;3&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;973437&#8243;]<strong>Dr. Graham Keith Dixon<\/strong>, was born in 1961 in St. Helens, United Kingdom, he pursued his academic studies in the UK, completing a Bachelor of Science in Applied Biology at the University of Bradford, followed by a PhD in Biochemistry at the University of Swansea.<\/p>\n<p data-start=\"338\" data-end=\"984\">Over the past 35 years, he has gained extensive experience in the pharmaceutical and biotechnology industries. Throughout his career, he has held a variety of leadership positions in both large pharmaceutical companies and the biotech sector. His roles have included positions in R&amp;D at AstraZeneca plc, as well as several C-level appointments at successful biotech companies: Chief Operating Officer (COO) at F2G Ltd; Chief Scientific Officer (CSO) at Entomed SA, Galapagos NV (AMS:GLPG), Addex Therapeutics SA (SWX:ADXN), Sensorion SA (EPA:ALSEN), and Onxeo SA (EPA:ONXEO); CEO of Neem Biotech Ltd; and Head of R&amp;D \/ CSO at Mithra (EBR: MITRA).<\/p>\n<p data-start=\"986\" data-end=\"1246\">He is currently serving as CEO of Estetra SRL and BCI Pharma, both wholly owned subsidiaries of the Hungarian pharmaceutical company Gedeon Richter. These organizations operate as the group\u2019s center of excellence for research and development in women\u2019s health.<\/p>\n<p>[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; uncode_shortcode_id=&#8221;202939&#8243; sep_color_type=&#8221;uncode-palette&#8221; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;630438&#8243;]Alongside his office as a member of the Supervisory Board, Dr. Graham Dixon is, a member of the administrative or supervisory bodies of and\/or a partner in the following companies and partnerships outside Formycon:<\/p>\n<p><strong>Currently<\/strong>: None<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][\/vc_tabs][vc_empty_space empty_h=&#8221;3&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;114327&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;198721&#8243; el_width=&#8221;60%&#8221;][vc_custom_heading heading_semantic=&#8221;h4&#8243; text_size=&#8221;h4&#8243; text_weight=&#8221;400&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;173113&#8243;]Additional information:[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;190695&#8243;]<\/p>\n<div class=\"uncode_text_column\">\n<p><a href=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2026\/03\/Entsprechenserklaerung_EN.pdf\" target=\"_blank\" rel=\"noopener\">Declaration of Conformity<\/a><\/p>\n<p><a href=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/Rules-Procedure_Supervisory-Board.pdf\" target=\"_blank\" rel=\"noopener\">Rules of Procedure for the Supervisory Board of Formycon AG<\/a><\/p>\n<p><a href=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2026\/04\/Verguetungsbericht_2025__EN.pdf\" target=\"_blank\" rel=\"noopener\">Compensation Report<\/a><\/p>\n<p><a href=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2026\/04\/ErklaerungzurUnternehmensfuehrung_2025_EN.pdf\">Corporate governance statement pursuant to Sections 289f, 315d of the German Commercial Code<\/a><\/p>\n<\/div>\n<p>[\/vc_column_text][vc_empty_space empty_h=&#8221;4&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]<\/p>\n","protected":false},"author":18,"featured_media":79620,"parent":78053,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-97056","page","type-page","status-publish","has-post-thumbnail","hentry","page_category-ir-update-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Supervisory Board - Formycon AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Supervisory Board - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T06:54:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/\",\"url\":\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/\",\"name\":\"Supervisory Board - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.formycon.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg\",\"datePublished\":\"2025-08-05T05:05:48+00:00\",\"dateModified\":\"2026-04-29T06:54:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#primaryimage\",\"url\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg\",\"contentUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg\",\"width\":1600,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.formycon.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Company\",\"item\":\"https:\/\/www.formycon.com\/en\/company\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Supervisory Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.formycon.com\/en\/#website\",\"url\":\"https:\/\/www.formycon.com\/en\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.formycon.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Supervisory Board - Formycon AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/","og_locale":"en_US","og_type":"article","og_title":"Supervisory Board - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/","og_site_name":"Formycon AG","article_modified_time":"2026-04-29T06:54:22+00:00","og_image":[{"width":1600,"height":800,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/","url":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/","name":"Supervisory Board - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg","datePublished":"2025-08-05T05:05:48+00:00","dateModified":"2026-04-29T06:54:22+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/05\/supervisory-board-formycon-keyvisual.jpg","width":1600,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/company\/supervisory-board-of-formycon-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Company","item":"https:\/\/www.formycon.com\/en\/company\/"},{"@type":"ListItem","position":3,"name":"Supervisory Board"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-05-12 17:00:23","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=97056"}],"version-history":[{"count":11,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97056\/revisions"}],"predecessor-version":[{"id":99804,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97056\/revisions\/99804"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media\/79620"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=97056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}